Toggle light / dark theme

Clinical trial shows taking blood pressure medication at night improves nocturnal and daytime control

Research led by Sichuan University in China has revealed that bedtime antihypertensive medication dosing improves nocturnal blood pressure control over morning dosing in patients with hypertension.

Hypertension is a major global health challenge. In China, nearly 300 million individuals live with elevated blood pressure and fewer than 17% achieve adequate control. Nocturnal pressure is often the most difficult to manage and can be a better predictor of heart attack and stroke than daytime readings.

Previous studies have examined the optimal timing for antihypertensive medication with conflicting evidence and substantial variability in study outcomes.

New gene tool leads to better treatments for complex diseases

Genetic changes can signal evidence of disease, but pinpointing which genes and what’s changed can be difficult.

But in a study of traits that offer clues to a person’s —such as lipid and and inflammation—a team of researchers at Case Western Reserve University devised a and tool to improve how genes and genetic changes that cause diseases are identified.

Their new approach could allow doctors to detect and treat so-called cardiometabolic diseases earlier in their development. Their findings were recently published in the journal Nature Communications.

Is Intelligence Genetic? Scientists Discover Heritable Brain State That Powers Cognitive Flexibility

Brain dynamics and cognition share genetic roots. Criticality may guide future brain health research. A recent study published on June 24 in PNAS presents strong evidence that brain criticality—the delicate balance between neural excitation and inhibition—is heavily influenced by genetic factors

Mysterious New Structure Discovered Hiding Inside Human Cells

After centuries of mapping the human body in ever-finer detail, scientists are still making discoveries. Here we are, in 2025, and a previously unknown cellular structure that could be vital to our health has just been added to the anatomy books.

The membrane-bound organelle appears to play a huge role in helping cells sort, discard, and recycle their contents. It’s called a hemifusome, and a team of scientists says it could shed new light on disease.

“This is like discovering a new recycling center inside the cell,” said biophysicist Seham Ebrahim of the University of Virginia. “We think the hemifusome helps manage how cells package and process material, and when this goes wrong, it may contribute to diseases that affect many systems in the body.”

Activin-A: Muscle Weakness In Cancer Survivors May Be Treatable

Tumors can destroy the blood vessels of muscles even when the muscles are nowhere close to the tumor. That is the key finding of a new study that my colleagues and I recently published in the journal Nature Cancer.

Muscle loss in cancer patients is a major health problem, but the exact causes of how precisely tumors affect muscles remain an active area of research.

Scientists in my lab were curious whether one explanation for the muscle loss in cancer patients could be that the cancer impairs the blood vessels that are necessary to supply nutrients and oxygen to muscles. Healthy blood vessels ensure that blood containing oxygen and nutrients is transported from the heart to all tissues and organs in the body, and then circulates back to the heart. Unhealthy blood vessels lose the ability to circulate sufficient blood and develop leaks, with nutrients seeping into the tissue prematurely and thereby cutting off the supply of nutrients to tissues that are further downstream.

LLNL researchers use AI to look for potential ALS treatments

Potential treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases may already be out there in the form of drugs prescribed for other conditions. A team of researchers from Lawrence Livermore National Laboratory (LLNL), Stanford University and the University of California, Los Angeles (UCLA) are using artificial intelligence and machine learning (AI/ML) to try to find them.

Clinical trials for new drugs can take up to 5–7 years, so repurposing existing drugs is one of the best ways to deliver treatments quickly. AI/ML can make it even faster. By analyzing long-term electronic health records (EHRs) of patients with ALS, the team can identify drugs — or combinations of drugs — prescribed for other conditions that may influence the progression of the disease. The drugs’ “off-target” effects may not only affect patient survival but also provide insight into how neurodegenerative diseases work and inform better therapies.

“If you talk to any ALS caregiver, you will be moved because the disease has such a grim prognosis, so being able to do something is tremendously motivating,” said Priyadip Ray, a staff scientist in LLNL’s Computational Engineering Division (CED) who leads the effort.

/* */